Kura Oncology (NASDAQ:KURA) reported quarterly losses of $(0.92) per share which missed the analyst consensus estimate of $(0.59) by 56.2 percent. This is a 318.18 percent decrease over losses of $(0.22) per share from the same period last year. The company reported quarterly sales of $17.336 million which missed the analyst consensus estimate of $53.554 million by 67.63 percent. This is a 67.83 percent decrease over sales of $53.883 million the same period last year.